BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schneider SA, Hizli B, Alcalay RN. Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism. Neurotherapeutics 2020;17:1378-92. [PMID: 32914362 DOI: 10.1007/s13311-020-00920-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Crotty GF, Schwarzschild MA. What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology 2022;99:34-41. [PMID: 35970592 DOI: 10.1212/WNL.0000000000200238] [Reference Citation Analysis]
2 Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C. Path to Parkinson Disease Prevention: Conclusion and Outlook. Neurology 2022;99:76-83. [PMID: 35970586 DOI: 10.1212/WNL.0000000000200793] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Niotis K, West AB, Saunders-Pullman R. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts. Neurology 2022;99:10-8. [PMID: 35970585 DOI: 10.1212/WNL.0000000000200812] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Sanchez-Mirasierra I, Ghimire S, Hernandez-Diaz S, Soukup SF. Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson's Disease. Front Cell Dev Biol 2022;10:921314. [PMID: 35874822 DOI: 10.3389/fcell.2022.921314] [Reference Citation Analysis]
5 Surface M, Balwani M, Waters C, Haimovich A, Gan-Or Z, Marder KS, Hsieh T, Song L, Padmanabhan S, Hsieh F, Merchant KM, Alcalay RN. Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease. Mov Disord 2022. [PMID: 35092096 DOI: 10.1002/mds.28936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cook L, Schulze J, Verbrugge J, Beck JC, Marder KS, Saunders-Pullman R, Klein C, Naito A, Alcalay RN; ClinGen Parkinson's Disease Gene Curation Expert Panel and the MDS Task Force for Recommendations for Genetic Testing in Parkinson's Disease., Clinical Genome Resource (ClinGen) Parkinson's Disease Gene Curation Expert Panel Authors., Movement Society Disorder (MDS) Task Force on Recommendations for Clinical Genetic Testing in Parkinson's Disease Authors. The commercial genetic testing landscape for Parkinson's disease. Parkinsonism Relat Disord 2021;92:107-11. [PMID: 34696975 DOI: 10.1016/j.parkreldis.2021.10.001] [Reference Citation Analysis]
7 Sabnis RW. Novel N-Heteroaryl Quinazolin-2-amine Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease. ACS Med Chem Lett 2021;12:1063-4. [PMID: 34267870 DOI: 10.1021/acsmedchemlett.1c00295] [Reference Citation Analysis]
8 Tanner CM, Ostrem JL. Therapeutic Advances in Movement Disorders. Neurotherapeutics 2020;17:1325-30. [PMID: 33452629 DOI: 10.1007/s13311-020-00988-2] [Reference Citation Analysis]
9 Hung AY, Schwarzschild MA. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics 2020;17:1393-405. [PMID: 33205384 DOI: 10.1007/s13311-020-00964-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]